A new trading day began on Tuesday, with Syndax Pharmaceuticals Inc (NASDAQ: SNDX) stock price down -6.50% from the previous day of trading, before settling in for the closing price of $9.85. SNDX’s price has ranged from $8.58 to $25.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -15.16% over the last five years. Meanwhile, its annual earnings per share averaged -2.51%. With a float of $82.47 million, this company’s outstanding shares have now reached $86.05 million.
The firm has a total of 270 workers. Let’s measure their productivity. In terms of profitability, gross margin is -3.44%, operating margin of -786.59%, and the pretax margin is -757.52%.
Syndax Pharmaceuticals Inc (SNDX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Syndax Pharmaceuticals Inc is 4.16%, while institutional ownership is 115.59%. The most recent insider transaction that took place on Jul 10 ’25, was worth 89,667. Before that another transaction happened on May 16 ’25, when Company’s Head of R&D, CMO bought 11,765 for $8.99, making the entire transaction worth $105,826. This insider now owns 35,165 shares in total.
Syndax Pharmaceuticals Inc (SNDX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.91 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -2.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.93% during the next five years compared to -15.16% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Here are Syndax Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.87, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -2.75 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
Analysing the last 5-days average volume posted by the [Syndax Pharmaceuticals Inc, SNDX], we can find that recorded value of 2.09 million was lower than the volume posted last year of 2.18 million. As of the previous 9 days, the stock’s Stochastic %D was 67.80%.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 7.53%, which indicates a significant decrease from 43.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.56 in the past 14 days, which was lower than the 0.78 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.12, while its 200-day Moving Average is $13.95. Now, the first resistance to watch is $9.77. This is followed by the second major resistance level at $10.33. The third major resistance level sits at $10.64. If the price goes on to break the first support level at $8.90, it is likely to go to the next support level at $8.59. Now, if the price goes above the second support level, the third support stands at $8.03.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats
With a market capitalization of 792.50 million, the company has a total of 86,047K Shares Outstanding. Currently, annual sales are 23,680 K while annual income is -318,760 K. The company’s previous quarter sales were 20,040 K while its latest quarter income was -84,850 K.
